Evidence map›Paper›PMID 30610545›Full record

ArticleInternational journal of clinical pharmacy2019

Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.

A Chastang, S Renet, J Corny, H Beaussier, A Petre, A Lillo-Lelouet, T T Phan Thi, Y Bézie

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pharmacological interactions between psychotropic drugs and anticancer treatments: implications for clinical practice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

A ChastangPharmacy Department, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.
S RenetPharmacy Department, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.
J CornyPharmacy Department, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.
H BeaussierClinical Research Center, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.
A PetrePharmacy Department, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.
A Lillo-LelouetCentre Régional de PharmacoVigilance, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015, Paris, France.
T T Phan ThiPharmacy Department, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.
Y BéziePharmacy Department, Groupe hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France. ybezie@hps.fr.ORCID http://orcid.org/0000-0003-4352-6996
Hôpital Paris Saint-Joseph · FRHôpital Européen Georges-Pompidou · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Citalopram and escitalopram can both induce dose-dependent QT prolongation. The risk of arrhythmia may be increased with concomitant use of other drugs that induce QT prolongation. Objective To evaluate the prevalence and impact of pharmacist interventions on the combination of citalopram or escitalopram with other drugs that induce QT prolongation. Setting A French hospital with 517 computerized beds. Method All cardiac adverse drug reactions (ADRs) related to citalopram or escitalopram reported to the French pharmacovigilance database (FPDB) were analyzed. Then, over a 6-month period, all computerized prescriptions including citalopram or escitalopram and drug-drug interactions (DDI) were analyzed by pharmacists using a computerized provider order entry system (DXCare

Indexed as

AdultAgedAnti-Arrhythmia AgentsAntipsychotic AgentsArrhythmias, CardiacCitalopramDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHumansLong QT SyndromeMaleMiddle AgedPharmacistsPharmacovigilancePharmacy Service, HospitalAnti-Arrhythmia AgentsAntipsychotic AgentsCitalopramCitalopramContraindicated drug–drug interactionsDrug safetyPharmacist interventionQT-prolonging drugs

Identifiers

PMID30610545
OpenAlexW2908042207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.